NABCO Resource Card on Breast Cancer Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

NEW YORK-The National Alliance of Breast Cancer Organizations (NABCO) has introduced the NABCO Resource Card, a quick reference guide to services and programs offered by the top breast cancer organizations in the United States.

NEW YORK—The National Alliance of Breast Cancer Organizations (NABCO) has introduced the NABCO Resource Card, a quick reference guide to services and programs offered by the top breast cancer organizations in the United States.

“Every day, we hear from women, ‘If I had only known about you,’” said Amy Langer, executive director of NABCO and a 12-year breast cancer survivor. “Even though there are many breast cancer resources available, too often women are not connecting with them. With support from Schering Corporation, we have created the NABCO Resource Card to offer a free directory to women and their families everywhere.”

One Million Cards

The card, sized to fit in a business envelope, concisely lists services in nine areas, including support groups, legal matters, clinical trials, volunteer groups, and information on breast cancer risks, diagnosis, and treatment. The toll-free telephone numbers of leading breast cancer organizations are provided.

One million of the cards will be distributed to more than 10,000 physicians’ offices and organizations cross the country. To receive a free NABCO Resource Card, call 1-800-610-5757.

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.